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Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis
cancer
A. Katagiri, Y. Tomita, T. Nishiyama, M. Kimura & S. Sato
Department of Urology, Niigata University School ofMedicine, Niigata, Japan.
Summary P-glycoprotein (Pgp) and pi-class glutathione S-transferase (GSTPI-1) are thought to be correlated
with multiple drug resistance. In immunohistochemical staining, non-seminomatous germ cell tumours, which
are more refractory than seminomas to anti-cancer chemotherapy, frequently expressed Pgp and GSTP1-1.
Western blot analysis demonstrated lower amount of GSTPl-l in seminoma than in teratoma. These results
suggest that Pgp and GSTPI-I might contribute to drug resistance in testis cancers
Multiple drug resistance (MDR) is a major problem in the
treatment of cancer and is reported to be attributed to
P-glycoprotein (Pgp) and glutathione metabolism (Kramer et
al., 1988; Mickisch et al., 1990). It is well known that malig-
nant tumours and cell lines which show marked resistance to
anti-cancer drugs frequently express Pgp, which is a 170-kDa
cell membrane glycoprotein thought to act as an energy-
dependent drug efflux pump (Gerlach et al., 1986). Phar-
macologically, cells overexpressing Pgp exhibit reduced int-
racellular accumulation of a number ofdrugs (Gerlach et al.,
1986; Dalton et al., 1989; Miller et al., 1991; Kanamaru et
al., 1989).
In the glutathione metabolism which is of special impor-
tance for cellular protection against free radicals and
exogenous compounds including anti-cancer drugs, GST is
thought to play the most important role in MDR (Kramer et
al., 1988). Human cytosolic GSTs are classified into four
groups, alpha, mu, pi and theta (Mannervik et al., 1992).
Among these isoenzymes, predominant expression and in-
creased activity of pi-class GST (GSTPI-1) is found in many
human tumour tissues and cell lines which show resistance to
anti-cancer drugs (Hara et al., 1990; Kodate et al., 1986;
Shiratori et al., 1987; Ail-Osman et al., 1990; Nakagawa et
al., 1988). GSTPI-I has also been considered as a potential
marker of neoplastic lesions in several organs (Kodate et al.,
1986; Niitsu et al., 1990; Shiratori et al., 1987).
Testis cancers are classified clinically into two groups,
seminomas and non-seminomatous germ cell tumours
(NSGCTs), which differ markedly in their sensitivity to
chemotherapeutic agents (Ellis et al., 1987). Therefore, our
interest was focused on the difference of Pgp and GSTPI-I
expression between these two types of testis cancer. In the
present study, we examined 26 cases of primary testis cancer
immunohistologically to investigate the heterogeneity of Pgp
and GSTPI-I expression.
Materials and methods
Patients andspecimens
Specimens were obtained from 26 patients who had under-
gone orchiectomy for testis cancer. Mean age at surgery was
36 years with a range of 6 months-87 years. Normal testes
were collected from patients who had undergone orchiectomy
for prostatic cancer. All tissue samples were embedded in
OCT compound (Miles Laboratories, Naperville, IL, USA)
after rinsing in phosphate-buffered saline (PBS), and then
snap-frozen in isopentane precooled in dry ice-acetone. These
blocks were stored at - 80°C before sectioned at 51. using a
cryostat. Histological examination was performed on
haematoxylin and eosin (H&E)-stained tissue sections. His-
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tological stage was determined according to the TNM
classification of malignant tumours (UICC, 1989).
Reagents
In this study we used a monoclonal antibody, JSB-1 (IgGj)
against Pgp (Sanbio Co., Am Uden, Holland), a polyclonal
antibody, mdr (ab-1) against Pgp (Oncogene Science Inc.,
Manhasset, NY, USA), and two polyclonal antibodies
against GSTPl-I raised against human placenta (Bioprep
Co., Dublin, Ireland, Cosmo Bio Co., Tokyo, Japan).
Immunoperoxidase staining
Immunoperoxidase staining was performed using the
streptavidin-biotin bridge technique as previously reported
(Tomita et al., 1990). Briefly, serial sections prepared in a
cryostat were air-dried for 30 min and fixed in cold acetone
for 10 min. After rehydration with PBS, the sections were
incubated in PBS containing 20% normal sheep serum or
normal donkey serum (Antibodies Inc., Davis, CA, USA) for
30 min and endogenous biotin was blocked using an
Endogenous Biotin Blocking Kit (Vector Laboratories, Burl-
ingame, CA, USA). The sections were then incubated with
primary antibody for 60min followed by incubation with
biotinylated anti-mouse or anti-rabbit immunoglobulin
(Amersham International, Amersham, Bucks, UK) diluted
1:100, containing 20% human type AB serum (Biological
Speciality Co., Landscale, PA, USA). Subsequently, they
were incubated with streptavidin peroxidase (Amersham)
diluted 1:100 for 45 min. Each step was followed by washing
in PBS with three changes of the buffer. The sections were
then immersed in 0.05% diaminobenzidine (Sigma Chemical
Co., St Louis, MO, USA) and 0.01% H202 in 0.05 M Tris
HCI buffer for 3-5 min to visualise the reaction products.
After washing in tap-water, specimens were counterstained
with Mayer's haematoxylin and mounted with Eukitt (O.
Kuldler, Freiburg, FRG) after dehydration in a graded
ethanol series and xylene.
As a negative control, the JSB-1 (murine) monoclonal
antibody was replaced by mouse monoclonal antibody of the
same subclass (IgG,), anti-Leul2 (Becton Dickinson, Moun-
tain View, CA, USA), and the (rabbit) polyclonal antibodies
were replaced by rabbit polyclonal antibody, anti-IL-6 (Gen-
zyme Co., Boston, MA, USA). As a positive control for Pgp,
proximal tubules in a kidney from a patient who underwent
nephrectomy for renal trauma were examined, and for
GSTPI-1, the staining pattern of trophoblast in term
placenta obtained from normal delivery was checked.
Western blot analysis
Tissue samples were homogenised in 2-3 volumes of 50mM
sodium phosphate buffer (pH 6.5 at 4C), sonicated for 30 s,
and centrifuged at 12,000g for 40min. Western blotting of
the supernatant was performed as described by Towbin et al.
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(Towbin et al., 1979). Samples were electrophoresed on 12% /
polyacrylamide gels. The gel was electro-blotted to Hybon
ECL super (Amersham) in a semi-dry apparatus (Bio-Rad
Lab., Richmond, CA, USA) for 1 h at 280 mA constant
current, using 25 mm Tris and 192 mm glycine in 20%
methanol as a transfer buffer. The blots were blocked in 5%
non-fat milk for 1 h and incubated for 1 h with either rabbit
antiserum to GSTPl-l (Bioprep), the same antibody used in
immunoperoxidase staining, or normal rabbit serum (Amer-
sham) as negative controls. The blots were then incubated
with HRP-conjugated protein A (Amersham) for 1 h. Each
step was followed by washing in 20 mm Tris buffer saline
(pH 7.6) with 0.5% Tween 20. Visualisation of washed blots
was performed with ECL Western blotting detection system
(Amersham) according to manual of manufacture. Molecular
weight was estimated by Rainbow Protein Molecular Weight
Markers (Ametersham). in ne(8% o 13seinoasandeiht Figure 1 Immunohistochemical detection of Pgp in teratoma
using mdr(ab 1)h The luminal site of glandular epithelial cells
showed intense positive staining. Bar = 75 tim.
Results .
Histopathological and clinicalfeatures of testis cancer a
Histopathological and clinical features were examined in eachSt
case and results are shown in Table I. In 26 cases of testis
cancer, 13 were seminomas and 13 were NSGCTs (11 mixed
germ cell tumours, one teratoma, and one yolk sac tumour).
Pgp and GSTPJ-J expression in normal testes
In this study, normal germ cells, Sertoli cells, and interstitial
cells were not stained with any antibodies used. Endothelial
cells were weakly stained with each antibody.
Pgp and GSTPJ-J expression in testis cancer
Pgp was detected in one (8%) of 13 seminomas and eight Figure 2 Immunohistochemical detection of GSTP1 1 in tera-
(62%) of 13 NSGCTs. One (8%) of 13 seminomas and eight toma. The focal expression was detected in the region imitating
(62%) of 13 NSGCTs were stained positively with anti- glands and smooth muscle. Bar =75Ism.
Table I Clinical feature and histopathological diagnosis
TNM UICC Histological Status
No. Age classification stage type (treatment)
1 29 TINOMO 1 S NED (RAD)
2 32 TINOMO 1 S NED (PVB)
3 47 T3NOMO 2 S NED
4 25 TINOMO I S NED
5 41 T2N2MO 4 S NED (PEBV, RPLND)
6 29 TINOMO 1 S NED (PVB)
7 62 T2N3MO 4 S -Died (PEBV)
8 35 T2NOMO 1 S NED
9 32 TINOMO 1 S NED
10 30 T2NOMO I S NED (bPEBV)
01 87 T2NOMO 1 T NED
12 49 T3NOMO 2 5 NED (RAD)
13 41 T2NOMO 1 S NED
14 39 T3NOMO 2 S,T NED (RAD)
15 17 T2NOMO 1 S,EC NED (PVB)
16 20 T3N2MO 4 EC,Y,C NED (PEPep, ElCp,
VAB-PE, RPLND)
17 32 T2NOMO 1 S,Y,EC,T NED
18 33 T1N2MO 4 S,T NED (PEBV, RPLND)
19 20 TINOMO 1 EC,T,Y NED (CpE)
20 36 TINOMO 1 T NED (PVB)
21 6M TINOMO 1 Y NED
22 16 T2N3Ml 4 EC,T,Y 'Died (PVB, RPLND,
PVB)
23 39 TINOMO 1 S,Y,EC NED
24 2Y7 IXT3N2M1 4 S,C,Y,EC17d aD,:ied (PE
25 33 TINOMO I EC,C,Y,T NED
26 25 T3N2M1 4 T,EC,Y Alive (PE)
S = seminoma; T = teratoma; EC = embryonal cell carcinoma; C = choriocarcinoma;
Y = yolk sac tumour; NED = no evidence of disease; A = actinomycin-D; B = bleo-
mycin; Cp = carboplatin; E =etoposide; I = ifosfamide; P = cisplatin; Pep = Peplo-
mycin; V =vinblastine; RAD = irradiation; RPLND = retroperitoneal lymph node
dissection; a= died during chemotherapy; b = chemotherapy against paraaortic lymph
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Table II Pgp and GSTPI-1 expression on testis cancer
Histological Pgp GSTPl-l
No. type JSB-1 mdr(ab-1) ab.J ab.2
1 S - - - -
2 S - - - -
3 S - - - -
4 S - - - -
5 S - - - -
6 S - - - -
7 S - - - -
8 S - - - -
9 S - - + -
10 S - + - -
11 S - - - -
12 S - - - -
13 S - - - -
14 S,T + (T) + (S,T) + (S,T) + (T)
15 S,EC _ +a(S,EC) +a(S,EC)
16 EC,Y,C - - - -
17 S,Y,EC,T + (T) +a (EC,T) + (T) + (T)
18 S,T + (T) + (S,T) + (S,T) + (S,T)
19 EC,T,Y _ +a(T) +a (T) + (T)
20 T + + + +
21 Y - - - -
22 EC,T,Y - +a(T) + (T) + (T)
23 S,Y,EC - - - -
24 S,C,Y,T - - - -
25 EC,C,Y,T - - - -
26 T,EC,Y + (T) + (T) + (T) + (T)
ab.1 = antibody against GSTPI-l (Bioprep Co., Dublin); ab.2 = antibody against
GSTPI-I (Cosmo BioCo.,Tokyo,Japan); a = stainedweakly orfocally; S = seminoma;
T = teratoma; EC = embryonal cell carcinoma; Y = yolk sac tumour; C = chorio-
carcinoma; Histological types which were stained positively are described in
parentheses.
GSTP1-1 antibodies (Tables II and III). Among NSGCTs, all
of seven teratomas were stained with all antibodies against
Pgp and GSTPI-1, glandular epithelial cells being most
strongly stained at their apical portion (Figures 1 and 2). The
distribution of the positively stained cases was similar in both
Pgp and GSTPI-1 (Table IV). Two of five embryonal cell
carcinomas showed weak staining with JSB-1 mdr(ab-1).
GSTP1-1 was detected in one of five embryonal cell car-
cinomas. The elements of yolk sac tumour did not react with
all antibodies used. Expression of Pgp or GSTP1-1 and
clinical stage were not correlated (Table V).
Western blot analysis ofGSTPJ-J
Figure 3 demonstrated immunoprecipitation of GSTPI-I of
Mr 23,000 both in teratoma (lane 1) and seminoma (lanes 2,
3). Seminoma (lanes 2, 3) showed lower intensity band of
GSTPI-l than teratoma (lane 1) on blotted membrane,
indicating lower amount of GSTP1-I in seminoma than
teratoma.
Discussion
A decrease of intracellular drug accumulation by efflux
through Pgp results in MDR of tumour cells (Gerlach et al.,
1986; Dalton et al., 1989; Miller et al., 1991; Kanamaru et
al., 1989). It has been reported that resistance to doxorubicin
and vinblastine is correlated to the expression of Pgp
(Mickisch et al., 1990; Miller et al., 1991). Recent studies
have also shown that MDR can be induced in drug-sensitive
cells by transfection of genes encoding Pgp (Ueda et al.,
1987). However, in a doxorubicin-resistant breast cancer cell
line with Pgp, drug resistance was not reversed completely
even when intracellular drug accumulation was increased,
suggesting that another mechanism operates in MDR apart
from Pgp (Kramer et al., 1988). Overexpression and in-
creased activity of GSTPI-1 are also found in tumour cells
which show resistance to anti-cancer drugs (Ail-Osman et al.,
1990; Shea et al., 1988). Therefore, GSTPI-I is thought to be
Table III Correlation between Pgp or GSTPI-I expression and
histological type
Histological Pgp GSTPI-I
type + - +
Seminoma 1 *12 1 *12
NSGCT 8 5 8 5
T-element 7 0 7 0
E-element 2 3 1 4
Y-element 0 5 0 5
NSGCT = non-seminomatous germ cell tumour; T = teratoma;
E = embryonal cell carcinoma; Y = yolk sac tumour. *P<0.05
compared with NSGCT (Fisher's exact test).
Table IV Relationship between expression of Pgp and GSTPI-1
Pgp negative Pgp positive
GSTPl-l negative 16 1
GSTPl-1 positive 1 8
P<0.01 (Fisher's exact test).
Table V Correlation between Pgp or GSTPI-l expression and clinical
stage
Stage Pgp GSTPl-I
(UICC 1989) + - + -
1 5 *11 5 *11
2 1 2 1 2
4 3 4 3 4
*Not significant (Fisher's exact test).
at least partly responsible for MDR. In fact, correlation
between GSTP1-I expression and resistance to platinum
compounds, alkylating agents, nitrosourea and doxorubicin
has been reported (Ail-Osman et al., 1990; Nakagawa et al.,
1988; Niitsu et al., 1990). However, acquisition of drug resis-
tance by transfection of cDNA of GST isoenzymes into
chemo-sensitive tumour cells is not consistent. (Puchalski et
al., 1990; Fairchild et al., 1990.)128 A. KATAGIRI et al.
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Figure 3 Western blot analysis of GSTPl-l. Five lag ofextracted
samples of teratoma (lanes 1, 4 from case 20) and seminomas
(lanes 2, 5 from case 8 and lanes 3, 6 from case 12) were
separated by SDS-PAGE under reducing conditions, transferred
to nitrocellulose membranes, incubated with rabbit antiserum to
GSTPI-l (lanes 1 to 3) or normal rabbit serum (lanes 4 to 6),
and visualised with peroxidase-conjugated second antibody and
substrates. Lower intensity of GSTPl-l in seminoma than in
teratoma is demonstrated in blotted membrane. Positions of
molecular weight are shown on the right.
Testis cancer is one of the tumours most sensitive to
chemotherapy, and the overall cure rate of disseminated
testis cancer to chemotherapy is as high as 70-80% (Wil-
liams et al., 1987). However, NSGCTs are rather resistant to
chemotherapy, and choriocarcinoma and teratoma with em-
bryonal cell carcinoma (teratocarcinoma) have been reported
to have a poor prognosis (Ellis et al., 1987; Williams et al.,
1987; Wettlaufer et al., 1984). Salvage surgery for the
residual mass after chemotherapy frequently reveals a residue
of mature teratoma (Ellis et al., 1987), suggesting resistance
of teratoma to chemotherapeutic agents. In this study, Pgp
and GSTPl-l were detected more frequently in NSGCTs,.
especially in teratomas, than in seminomas, and a significant
difference was noticed (P<0.05). This suggests that the ex-
pression of Pgp or GSTPl-l could be an indicator of sen-
sitivity to anti-cancer drugs. A previous study showed
GSTPl-l expression in all histological types of testis cancer
immunohistochemically (Klys et al., 1992). However, Wes-
tern-blot analysis performed in the present study demon-
strated lower intensity of GSTP1-1 in seminoma than in
teratoma on the blotted membrane, suggesting lower
amounts of GSTP1-1 in seminoma than in teratoma (Figure
3).
Each element of teratoma, including epithelial cells,
smooth muscle cells, and chondrocytes, showed a similar
staining pattern to that of the corresponding normal tissue
reported previously (Cordon-Cardo et al., 1990; Kantor et
al., 1991). Thus, the expression of Pgp or GSTPI-I in
teratoma might be related to the degree of differentiation,
which has also been reported for renal cell carcinoma
(Kanamaru et al., 1989). Differentiated tissues often show
less susceptibility to anti-cancer drugs, and that is thought
to be attributed to low proliferative activity. A recent study
demonstrated that proliferative activity detected by thy-
midine labelling index was inversely correlated with expres-
sion of Pgp or GSTPI-1 (Volm et al., 1992). Therefore, the
resistance mechanism mediated by Pgp or GSTPI-1, which is
associated with low proliferative activity, might contribute at
least partly to refractoriness to chemotherapy in differ-
entiated tumours.
In this study, expression of Pgp correlated positively with
that of GSTPI-I (P<0.01), as in the report of lung cancer
(Volm et al., 1992). This correlation is unlikely to derive
from the character of the original tissue because previous
reports showed weak or no expression of Pgp or GSTP1-I in
normal germ cells (Cordon-Cardo et al., 1990; Kantor et al.,
1991). At present, there are no data on the existence of
co-regulation mechanisms for Pgp and GSTP1-1.
Finally, our results suggest that Pgp or GSTP1-1 expres-
sion, predominantly in teratoma, might be correlated with
the difference in sensitivity to chemotherapy of different his-
tological types of testis cancer. However, correlation between
the expression of Pgp or GSTP1-1 and clinical factors includ-
ing prognosis in more cases of advanced stage or refractory
history remains to be examined.
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